Investment
Features
FeesSafety
Academy
More
Pluang+

Market correction likely not over as investor optimism remains high, says Wall of Worry Indicator.

Market News
28 Jul 2026
Seeking Alpha
View Source
Neutral
pluang ai news

The Wall of Worry Indicator (WOW) suggests the current market correction is not finished due to persistent investor optimism. Despite a strong rally from April to June, sentiment never reached extreme greed levels, indicating potential for further gains after the correction. The indicator relies on contrary opinion theory, which uses investor sentiment extremes to predict market turns rather than fundamentals alone. More bearish sentiment is needed before a sustainable market rally can occur.

More News

AGC Biologics secures multi-year, multi-million dollar commercial production deal for new Yokohama biopharma site.

AGC Biologics secures multi-year, multi-million dollar commercial production deal for new Yokohama biopharma site.

AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...

Company Fundamentals
Bullish
1 hour ago
AGC Biologics secures multi-year commercial manufacturing deal worth hundreds of millions for new Yokohama site.

AGC Biologics secures multi-year commercial manufacturing deal worth hundreds of millions for new Yokohama site.

AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...

Company Fundamentals
Bullish
1 hour ago
AGC Biologics signs multi-year commercial production deal worth hundreds of millions for new Yokohama facility.

AGC Biologics signs multi-year commercial production deal worth hundreds of millions for new Yokohama facility.

AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...

Company Fundamentals
Bullish
1 hour ago
Seagate surges on Q4 earnings beat and AI-driven data storage demand

Seagate surges on Q4 earnings beat and AI-driven data storage demand

Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...

Company Fundamentals
Bullish
3 hours ago
Replimune stock plunges 38% after FDA flags clinical trial issues for skin cancer drug

Replimune stock plunges 38% after FDA flags clinical trial issues for skin cancer drug

Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw signif...

Market News
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App